Author Interviews, Cancer Research, Dermatology, JAMA / 06.10.2025

MedicalResearch.com Interview with: [caption id="attachment_70681" align="alignleft" width="167"]Dr. Wheless Dr. Wheless[/caption] Lee Wheless, MD, PhD Assistant Professor Department of Dermatology Department of Medicine, Division of Epidemiology Vanderbilt University Medical Center Staff Physician Tennessee Valley Health System VA Medical Center MedicalResearch.com: What is the background for this study? Response: Nicotinamide has been in use for skin cancer prevention for at least a decade. A more recent trial among solid organ transplant recipients (SOTR) specifically concluded that there was no benefit in this population. While that study had a number of issues, it really led dermatologists to question whether it was efficacious. This coupled with another study around the same time that suggested that metabolites of nicotinamide might increase the risk of major adverse cardiovascular events (MACE). My group earlier this year conducted a similar study to this one showing that we really did not observe any increase in MACE at the population level. We then turned to address of the question of if nicotinamide was actually useful in reducing skin cancer risk.
Author Interviews, Dermatology, Medical Imaging, Melanoma / 14.04.2025

MedicalResearch.com Interview with: [caption id="attachment_67909" align="alignleft" width="150"]Pau Rosés-Gibert, MDDermatology Department, Hospital Clínic Barcelona University of Barcelona, Fundació Clínic per la recerca biomédica, Institut d’Investigació Biomèdica August Pi i Sunyer, IDIBAPS Diagnosis Dermatologica, Dermavision Solutions Barcelona, Spain and Dermatology Department, Hospital de Figueres, Figueres, Spain Dr. Gibert[/caption] Pau Rosés-Gibert, MD Dermatology Department, Hospital Clínic Barcelona University of Barcelona, Fundació Clínic per la recerca biomédica, Institut d’Investigació Biomèdica August Pi i Sunyer, IDIBAPS Diagnosis Dermatologica, Dermavision Solutions Barcelona, Spain and Dermatology Department, Hospital de Figueres, Figueres, Spain MedicalResearch.com: What is the background for this study? Response: Skin cancer monitoring, particularly in high-risk patients with atypical mole syndrome, traditionally relies on total body photography (TBP) combined with digital dermoscopy. This approach, though effective, is slow, labor-intensive, and prone to oversight since clinicians must manually locate and image individual lesions. Recent improvements in automated imaging systems, lighting, and dermoscopy software have raised the potential for fully autonomous systems to streamline this process — leading to the development of the autonomous total body photographic and dermoscopic device tested in this study.
Author Interviews, Dermatology, JAMA / 15.05.2023

MedicalResearch.com Interview with: [caption id="attachment_60425" align="alignleft" width="151"]Matthew Zirwas, MDFounder, Bexley Dermatology Research Clinic Bexley, OH 43209 Dr. Zirwas[/caption] Matthew Zirwas, MD Founder, Bexley Dermatology Research Clinic Bexley, OH 43209 MedicalResearch.com: What is the background for this study? How does Roflumilast differ from other treatments for seb derm? Response: Seborrheic dermatitis affects up to 5% of the population globally and can have major impacts on quality of life. Treatment regimens are often complicated given the association of seborrheic dermatitis to hair bearing areas of the body, requiring multiple treatments for different parts of the body. Our phase 2 study aimed to understand the efficacy and safety of once-daily roflumilast foam 0.3% in adults with seborrheic dermatitis on their scalp, face and trunk. Roflumilast foam is a selective and highly potent phosphodiesterase (PDE) 4 inhibition that is being studied for a range of inflammatory skin conditions.